ER-β expression in large bowel adenomas: Implications in colon carcinogenesis

Leo, Alfredo Di; Barone, M.; Maiorano, Eugenio; Tanzi, S.; Piscitelli, Domenico; Marangi, Stefania; Lofano, Katia; Ierardi, Enzo; Principi, M.; Francavilla, A.

doi:10.1016/j.dld.2007.10.018

Cited by 50 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The two distinct estrogen receptors (ERα and ERβ) tend to respond differently to estrogen. The high proliferative activity triggered by estrogen is related to its connection to the ERα, which can help tumoral development by increasing the probability of genetic mutations [37]. In contrast, the ERβ forms heterodimers with the ERα blocking their proliferative activity by suppression of oncogenic transcription factors (e.g.…”

Section: Discussionmentioning

confidence: 99%

KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients

et al. 2014

View full text Add to dashboard Cite

BackgroundKRAS mutations are frequently found in colorectal cancer (CRC) indicating the importance of its genotyping in the study of the molecular mechanisms behind this disease. Although major advances have occurred over the past decade, there are still important gaps in our understanding of CRC carcinogenesis, particularly whether sex-linked factors play any role.MethodsThe profile of KRAS mutations in the Brazilian population was analyzed by conducting direct sequencing of KRAS codons 12 and 13 belonging to 8,234 metastatic CRC patient samples. DNA was extracted from paraffin-embedded tissue, exon 1 was amplified by PCR and submitted to direct sequencing. The data obtained was analysed comparing different geographical regions, gender and age.ResultsThe median age was 59 years and the overall percentage of wild-type and mutated KRAS was 62.8% and 31.9%, respectively. Interestingly, different percentages of mutated KRAS patients were observed between male and female patients (32.5% versus 34.8%, respectively; p = 0.03). KRAS Gly12Asp mutation was the most prevalent for both genders and for most regions, with the exception of the North where Gly12Val was the most frequent mutation found.ConclusionsTo the best of our knowledge this is one of the largest cohorts of KRAS genotyping in CRC patients and the largest to indicate a higher incidence of KRAS mutation in females compared to males in Brazil. Nevertheless, further research is required to better address the impact of gender differences in colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Results showed that ERβ expression was significantly reduced in both adenomatous tissue with high levels of dysplasia and in carcinomatous tissues compared with normal mucosa ( P <.001). Further, in clinical samples from 25 patients with colonic polyps compared with 25 controls, expression of ERβ was demonstrated to be significantly lower in the polyps than in controls (10.1% ± 5.5% vs 44.2% ± 13.7%; P <.03) [47]. Konstantinopoulos and colleagues demonstrated similar results, with significantly reduced expression of ERβ in adenomatous tissue compared with neighboring healthy tissue ( P <.001) [37].…”

Section: Estrogen Receptor Beta (Erβ) Has a Role In Crcmentioning

confidence: 94%

Estrogen receptor beta as target for colorectal cancer prevention

et al. 2016

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a leading cause of death in the United States. Despite its slow development and the capacity for early diagnosis, current preventive approaches are not sufficient. However, a role for estrogen has been demonstrated in multiple epidemiologic studies, which may benefit CRC prevention. A large body of evidence from preclinical studies indicates that expression of the estrogen receptor beta (ERβ/ESR2) demonstrates an inverse relationship with the presence of colorectal polyps and stage of tumors, and can mediate a protective response. Natural compounds, including phytoestrogens, or synthetic ERβ selective agonists, can activate or upregulate ERβ in the colon and promote apoptosis in preclinical models and in clinical experience. Importantly, this activity has been associated with a reduction in polyp formation and, in rodent models of CRC, has been shown to lower incidence of colon adenocarcinoma. Collectively, these findings indicate that targeted activation of ERβ may represent a novel clinical approach for management of colorectal adenomatous polyps and prevention of colorectal carcinoma in patients at risk for this condition. In this review, we discuss the potential of new chemopreventive or dietary approaches based on estrogen signaling.

show abstract

“…Decreased ER β is observed in colonic polyps and colon cancer. ER α expression does not change in patients with colonic polyps; however, in colon cancer, ER α levels increase in men and not in women (Di Leo et al 2008; Nussler et al 2008). These data suggest sex-specific effects related to the ER α .…”

Section: Non-target Tissue Cancers and Ermentioning

confidence: 95%

Estrogen receptors and human disease: an update

2012

View full text Add to dashboard Cite

A myriad of physiological processes in mammals are influenced by estrogens and the estrogen receptors (ERs), ERα and ERβ. As we reviewed previously, given the widespread role for estrogen in normal human physiology, it is not surprising that estrogen is implicated in the development or progression of a number of diseases. In this review, we are giving a 5-year update of the literature regarding the influence of estrogens on a number of human cancers (breast, ovarian, colorectal, prostate, and endometrial), endometriosis, fibroids, and cardiovascular disease. A large number of sophisticated experimental studies have provided insights into human disease, but for this review, the literature citations were limited to articles published after our previous review (Deroo and Korach in J Clin Invest 116(3):561–570, 2006) and will focus in most cases on human data and clinical trials. We will describe the influence in which estrogen’s action, through one of or both of the ERs, mediates the aforementioned human disease states.

show abstract

ER-β expression in large bowel adenomas: Implications in colon carcinogenesis

Cited by 50 publications

References 23 publications

KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients

KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients

Estrogen receptor beta as target for colorectal cancer prevention

Estrogen receptors and human disease: an update

Contact Info

Product

Resources

About